Prothena | PRTA - Loan Capital


Prothena reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
MacroGenics USD 70.26M 4K Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Ultragenyx Pharmaceutical USD 782.75M 11.3M Jun/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025